LXEO

Conviction 25HealthcareScan · Mon, Aug 10, 2026

LXEO$4.63-3.74%

ResistanceSupportVol 14Insider sell

Vol MA14 1.18M

May 11May 28Jun 16Jul 6Jul 23Aug 10

Lexeo Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.lexeotx.com ↗

Price4.63

Change-3.74%

Gap+0.31%

Rel volume1.55×

Avg volume1.01M

Avg $ vol4.65M

SMA 204.54

SMA 504.63

SMA 2006.79

Price vs 50+0.03%

Price vs 200-31.85%

MA stackmixed

50/200 cross—

Supertrendup · 4.08

RSI (14)51

MACD hist0.04

MACD crossbull · 2d

Stoch %K / %D63 / 66

ADX (14)11

+DI / −DI21 / 16

RSI divergence—

MACD divergence—

ATR %+6.57%

ADR %6.37%

52w high10.63

52w low4.13

From 52w high-56.44%

Above 52w low+12.11%

New 52w highNo

SqueezeOn · 3d

Bollinger width16.98%

%B0.62

Donchian pos62.87%

Donchian high5.01

Donchian low3.99

AVWAP (52w high)6.17

vs AVWAP high-24.99%

AVWAP (52w low)4.54

vs AVWAP low+2.05%

OBV trendUp

Chaikin MF (20)-0.00

Today vs 20d1.55×

Avg vol (14d)1.18M

Avg vol (20d)1.01M

Avg $ vol (20d)4.65M

Market cap363.56M

RS 3m (vs SPY)-23.05%

RS 6m (vs SPY)-44.30%

RS line new highNo

Trend template1/8

Technical rank23.0

1 week+10.24%

1 month-3.94%

3 months-20.58%

6 months-35.34%

1 year+4.04%

YTD-51.82%

P/E-3.64

P/B1.57

P/S555.89

P/FCF-3.67

EPS-1.86

Div yield—

ROE-43.18%

ROA-39.93%

Debt/Eq—

Current14.16

EV/EBITDA-2.68

Gross margin—

Net margin—

Rev growth—

EPS growth-1.66%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value291.79M

Revenue531K

Net income-20.2M

Gross profit—

Free cash flow-98.96M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out78.52M

Employees59

ListedFri, Nov 3, 2023

Free float76.64M

Float %97.6%

Short interest16.35M

Days to cover19.6d

Short volume82.7%

Squeeze score93 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction25 / 100

Pattern quality—

Tech rank23.0 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.36

Support4.16

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LXEO

All disclosures →

No recent disclosed trades by Congress in LXEO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LXEO · 7 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Altschuler Steven Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
Agger Mette Kirstine Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
CHOLMONDELEY PAULA H Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
COOPERSTONE BRENDA Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
DIAZ REINALDO M Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
Van Hauwermeiren Timothy Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
Tanguler Tolga Director · Stock Option (right to buy) · 2026-06-25	Grant	35K	—	2026-06-25	2026-06-29
Townsend Richard Nolan Chief Executive Officer · Common Stock · 2026-05-18	Sell	3.34K	$17K	2026-05-18	2026-05-20
Otero Jose Manuel Chief Operating Officer · Common Stock · 2026-05-18	Sell	1.3K	$7K	2026-05-18	2026-05-20

SEC filings

EDGAR filings in LXEO · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.